Report Overview

The EU Endometriosis Treatment Market was valued at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, growing at aCAGR of XX% during the forecast period

Endometriosis is an estrogen-dependent gynecological disease, characterized by endometrium outside the uterus, affecting 10% of reproductive-aged women, associated with pelvic pain. Endometriosis is the resultant of the growth of endometrial tissue on the bowel, ovaries, and tissues lining the pelvis. The hormonal changes associated with the menstrual cycle impact the misplaced endometrial tissue that results in the area becoming inflamed which causes pain. Treatment can be with medications and/or surgery depending on symptoms, lesions, desired outcome, and patient choice. Contraceptive steroids, non-steroidal anti-inflammatory medications, and analgesics (painkillers) are common therapies



Market Growth Drivers

The growth factor are availability of enhanced medications, growing geriatric population, growing awareness rate for the disease, and increasing government funding for the treatment of endometriosis. EU occupies a prominent market position. The market position held is resultant of the continuous growth of the healthcare sector and rising investment in the industry